Travere Therapeutics (TVTX) Net Cash Flow (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Net Cash Flow came in at -$14.6 million in Q1 2026, down 619.3% YoY from $2.8 million in Q1 2025, and up 16.41% on a QoQ basis from -$17.5 million in Q4 2025.
Travere Therapeutics (TVTX) Net Cash Flow (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Net Cash Flow data on file, last reported at -$14.6 million in Q1 2026.
- Quarterly Net Cash Flow fell 619.3% year-over-year to -$14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (down 20.59% YoY) and the FY2025 annual result came in at $32.2 million, up 2432.15% from the prior year.
- Net Cash Flow grew to -$14.6 million in Q1 2026, from -$17.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $91.8 million in Q1 2022 to a low of -$132.6 million in Q4 2023.
- A 5-year average of -$7.7 million and a median of -$11.0 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow jumped 783.26% — and 2026, when it sank 619.3%.
- Tracing TVTX's Net Cash Flow over 5 years: stood at -$90.2 million in 2022, then sank by 47.07% to -$132.6 million in 2023, then surged by 117.14% to $22.7 million in 2024, then sank by 176.92% to -$17.5 million in 2025, then climbed by 16.41% to -$14.6 million in 2026.
- The last three Net Cash Flow figures came in at -$14.6 million (Q1 2026), -$17.5 million (Q4 2025), and $35.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 39.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.30 Mn |
| Jun 30, 2026 | 39.30 Mn |
| Mar 31, 2026 | -14.61 Mn |
| Mar 31, 2026 | -14.61 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Sep 30, 2025 | 35.57 Mn |
| Sep 30, 2025 | 35.57 Mn |
| Jun 30, 2025 | 11.31 Mn |
| Jun 30, 2025 | 11.31 Mn |
| Mar 31, 2025 | 2.81 Mn |
| Mar 31, 2025 | 2.81 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | -10.95 Mn |
| Jun 30, 2024 | -10.95 Mn |
| Mar 31, 2024 | -14.53 Mn |
| Mar 31, 2024 | -14.53 Mn |